Cadila Healthcare Limited has entered into a definitive agreement with Shilpa Medicare Limited, a contract manufacturing organization to produce mutually agreeable doses of ZyCoV-D. The company also entered into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
505 INR | +1.25% | -5.68% | +52.85% |
Apr. 18 | Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US | MT |
Apr. 17 | Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,959 KRW | -11.56% | -2.05% | 122M | ||
982.2 INR | +1.44% | -1.53% | 11.83B | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+52.85% | 525M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- SHILPAMED Stock
- News Shilpa Medicare Limited
- Cadila Healthcare Limited Entered into A Definitive Agreement with Shilpa Medicare Limited and Enzychem Lifesciences